Prognostic Significance of Serum Uric Acid and Gamma-Glutamyltransferase in Patients with Advanced Gastric Cancer

الملخص EN

Purpose.

In this study, we aim to evaluate the prognostic role of serum uric acid and gamma-glutamyltransferase in advanced gastric cancer patients.

Methods.

A total of 180 patients pathologically diagnosed with advanced gastric cancer were included in this retrospective study.

We used time-dependent receiver operating characteristic (ROC) curves to identify the optimal cut-off value of serum uric acid (UA) and gamma-glutamyltransferase (GGT).

Survival analysis was performed using the Kaplan–Meier method and log-rank test, and multivariate Cox regression analyses were applied.

A nomogram was formulated, and the calibration and discrimination of the nomogram were determined by calibration curve and concordance index (C-index).

We validated the results using bootstrap resampling and a separate study on 60 patients collected from 2015 to 2017 using the same criteria in other medical center.

Results.

Both higher serum uric acid (>228 μmol/L) and higher gamma-glutamyltransferase (>14 U/L) had worse OS and PFS.

Univariate analysis indicated that serum uric acid (UA) (p<0.001 and p<0.001) and gamma-glutamyltransferase (GGT) (p<0.001 and p=0.044) were significantly related to overall survival (OS) and progression-free survival (PFS), respectively.

Multivariate analysis revealed serum uric acid (UA) and gamma-glutamyltransferase (GGT) were independent prognostic factors for OS (p=0.012, p=0.001).

The optimal agreement between actual observation and nomogram prediction was shown by calibration curves.

The C-indexes of the nomogram for predicting OS and PFS were 0.748 (95% CI: 0.70-0.79) and 0.728 (95% CI: 0.6741-0.7819), respectively.

The results were confirmed in the validation cohort.

Conclusion.

We observed that both serum UA and GGT were poor prognostic factors in patients with advanced gastric cancer.

And we also formulated and validated a nomogram which can predict individual survival for advanced gastric cancer patients.